Investigators are assessing whether treatment with the angiotensinogen-targeting RNAi agent reduces patients' risk of cardiovascular disease.
Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback